Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases.

CONCLUSION: The longterm efficacy of the PPSV23 vaccination seems to be preserved among patients with RA, PsA, AS, and IBD-associated SpA for at least 10 years. Efficacy is slightly impaired by MTX, but it is not affected by biologics. These findings suggest that revaccination after 5 years might not be needed for all, and testing the antibody titers should be considered to identify those who may benefit from revaccination. PMID: 26773117 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26773117?dopt=Abstract

Source: J Rheumatol - January 15, 2016 Category: Rheumatology Authors: Broyde A, Arad U, Madar-Balakirski N, Paran D, Kaufman I, Levartovsky D, Wigler I, Caspi D, Elkayam O Tags: J Rheumatol Source Type: research